Becker's Healthcare June 30, 2022
Jakob Emerson

It may feel like the walls are closing in around the pharmacy benefit manager industry. In less than a month’s time, bipartisan legislation was introduced in Congress to create more regulations around the drug middlemen, and the Federal Trade Commission launched an inquiry into the six largest PBMs and their practices.

That’s not to mention that in 2021 alone, 18 state legislatures passed or had legislation become effective that involves PBM licensing or registration requirements. 

“I think they’re feeling the pressure because the business model is under threat,” Prescryptive Health CEO Chris Blackley told Becker’s. “They know they have to transform, but it’s very hard and very difficult to turn a big ship.”

Prescryptive is a Redmond, Wash.-based PBM that specializes in drug price transparency and describes itself...

Today's Sponsors

Oliver Wyman
Patient Bond
pCare

Today's Sponsors

Amwell
Oliver Wyman

Today's Sponsor

Patient Bond

 
Topics: Congress / White House, Govt Agencies, Pharma, Pharma / Biotech, Regulations
House decision on drug price negotiations may have little impact on drug industry, some say
Pharma prepares to continue fight as drug pricing bill passes House
House passes bill extending ACA subsidies, allowing Medicare drug price negotiations
Improving End-to-End Traceability and Pharma Supply Chain Resilience with Blockchain
Congress passes reconciliation bill with Marketplace, Medicare drug provisions